The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 1 - 10 of 56 results
News
|
|
1 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
3 min read
News
|
|
1 min read
News
|
|
1 min read
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read